Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

• Status: Completed
• Trial end date: 2012-04-18
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Recurrent or metastatic Squamous Cell Cancer of the Head and Neck;

• Measurable disease;

• Eastern Cooperative Oncology Group (ECOG) 0-1 in Stage 1 = first 23 patients;

• Eastern Cooperative Oncology Group (ECOG) 0-2 in Stage 2 = 33 patients;

Exclusion Criteria:

• prior therapy for recurrence;

• platelets < 75,000;

• prior Epidermal Growth Factor Receptor (EGFR) therapy;

• interstitial lung disease;

• primary of nasopharynx